Hubert Schrezenmeier to Middle Aged
This is a "connection" page, showing publications Hubert Schrezenmeier has written about Middle Aged.
Connection Strength
0.078
-
Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing. J Infect Dis. 2021 03 03; 223(5):796-801.
Score: 0.015
-
Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014 May; 99(5):922-9.
Score: 0.009
-
Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest. 2021 10 15; 131(20).
Score: 0.004
-
Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021 07 15; 131(14).
Score: 0.004
-
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021 06 15; 6(60).
Score: 0.004
-
Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)-a report on phase III. Ann Hematol. 2019 Jul; 98(7):1547-1559.
Score: 0.003
-
Gender, cholinesterase, platelet count and red cell count are main predictors of peripheral blood stem cell mobilization in healthy donors. Vox Sang. 2019 Apr; 114(3):275-282.
Score: 0.003
-
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. Am J Hematol. 2019 01; 94(1):E37-E41.
Score: 0.003
-
Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018 10 09; 2(19):2543-2549.
Score: 0.003
-
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018 09 11; 2(17):2176-2185.
Score: 0.003
-
Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. Stem Cell Res Ther. 2018 08 09; 9(1):213.
Score: 0.003
-
Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects. Haematologica. 2018 09; 103(9):1527-1534.
Score: 0.003
-
First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012. Am J Hematol. 2018 05; 93(5):643-648.
Score: 0.003
-
Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition. Haematologica. 2017 12; 102(12):e499-e501.
Score: 0.003
-
Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients. Haematologica. 2017 11; 102(11):1947-1955.
Score: 0.003
-
Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Intern Med J. 2017 Sep; 47(9):1026-1034.
Score: 0.003
-
Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study. PLoS One. 2017; 12(1):e0169512.
Score: 0.003
-
Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation. Haematologica. 2017 04; 102(4):796-803.
Score: 0.003
-
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. Ann Hematol. 2017 Feb; 96(2):171-181.
Score: 0.003